stoxline Quote Chart Rank Option Currency Glossary
  
Annovis Bio, Inc. (ANVS)
2.58  0.06 (2.38%)    02-12 16:00
Open: 2.52
High: 2.58
Volume: 398,174
  
Pre. Close: 2.52
Low: 2.455
Market Cap: 50(M)
Technical analysis
2025-02-12 4:43:00 PM
Short term     
Mid term     
Targets 6-month :  5.05 1-year :  6.42
Resists First :  4.33 Second :  5.5
Pivot price 3.7
Supports First :  2.44 Second :  2.03
MAs MA(5) :  2.73 MA(20) :  4.05
MA(100) :  6.46 MA(250) :  7.99
MACD MACD :  -0.8 Signal :  -0.6
%K %D K(14,3) :  4.3 D(3) :  3.4
RSI RSI(14): 19.7
52-week High :  20 Low :  2.44
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ANVS ] has closed above bottom band by 21.3%. Bollinger Bands are 99.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.58 - 2.6 2.6 - 2.61
Low: 2.42 - 2.44 2.44 - 2.45
Close: 2.55 - 2.58 2.58 - 2.61
Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Headline News

Tue, 11 Feb 2025
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline - MSN

Mon, 10 Feb 2025
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN

Fri, 07 Feb 2025
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Fri, 07 Feb 2025
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN

Fri, 07 Feb 2025
Annovis Bio CEO to Reveal Critical Alzheimer's Drug Development Milestones - Key Phase 3 Data - StockTitan

Tue, 04 Feb 2025
Alzheimer's Drug Developer Annovis Secures Critical $21M Funding for Final-Stage Trial - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 14 (M)
Shares Float 11 (M)
Held by Insiders 20.3 (%)
Held by Institutions 9.4 (%)
Shares Short 2,150 (K)
Shares Short P.Month 1,560 (K)
Stock Financials
EPS -4.22
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.52
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -154.6 %
Return on Equity (ttm) -596.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -23 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -0.62
PEG Ratio 0
Price to Book value 4.86
Price to Sales 0
Price to Cash Flow -1.56
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android